On Monday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) opened lower -6.70% from the last session, before settling in for the closing price of $18.35. Price fluctuations for FDMT have ranged from $9.44 to $36.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 111.29% over the last five years. Company’s average yearly earnings per share was noted -10.49% at the time writing. With a float of $43.53 million, this company’s outstanding shares have now reached $51.70 million.
The firm has a total of 147 workers. Let’s measure their productivity.
4D Molecular Therapeutics Inc (FDMT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of 4D Molecular Therapeutics Inc is 15.80%, while institutional ownership is 97.49%. The most recent insider transaction that took place on Jul 16 ’24, was worth 47,442. In this transaction Chief Legal Officer of this company sold 1,750 shares at a rate of $27.11, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Jul 11 ’24, when Company’s Chief Legal Officer sold 1,996 for $25.00, making the entire transaction worth $49,900. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 3/31/2024, the company posted -0.77 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.81) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.49% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Check out the current performance indicators for 4D Molecular Therapeutics Inc (FDMT). In the past quarter, the stock posted a quick ratio of 32.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -3.21 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 1.24 million was better than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 26.03%. Additionally, its Average True Range was 2.03.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 13.44%, which indicates a significant decrease from 20.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 203.60% in the past 14 days, which was higher than the 96.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.58, while its 200-day Moving Average is $21.47. Now, the first resistance to watch is $18.11. This is followed by the second major resistance level at $19.09. The third major resistance level sits at $19.81. If the price goes on to break the first support level at $16.41, it is likely to go to the next support level at $15.69. Should the price break the second support level, the third support level stands at $14.71.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are currently 51,703K shares outstanding in the company with a market cap of 885.10 million. Presently, the company’s annual sales total 20,720 K according to its annual income of -100,840 K. Last quarter, the company’s sales amounted to 30 K and its income totaled -32,400 K.
